NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
Clinical Trials
10 trialsNCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00452569 2019-11-18
OPTIMUM
Celgene
Phase 3 Completed
NCT00657488 2019-10-18
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
Phase 2/3 Completed
NCT00097981 2017-04-07
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00934154 2013-08-15
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Erkim Ilac A.S.
Phase 3 Completed
NCT00531453 2012-01-26
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed